Remora Biotech
Marco Alessandrini currently serves as the Head of Early Stage Ventures in Cell and Gene Therapy at Remora Biotech, a position held since May 2025. Prior experience includes roles as Chief Technology Officer and Chief Executive Officer at Antion Biosciences SA from November 2020 to May 2025, and as a Senior Scientist at Université de Genève, focusing on translational research from July 2016 to September 2020. Early career involvement includes consulting and post-doctoral work at the Institute for Cellular and Molecular Medicine, University of Pretoria, from January 2011 to June 2016, and managing the Clinical Trials Division at Key Oncologics from September 2008 to December 2010. Educational qualifications consist of a PhD in Biochemistry and Molecular Biology from North-West University and an MSc in Biochemistry from Potchefstroom University for CHE.
This person is not in any teams
This person is not in any offices
Remora Biotech
Immunotherapy has an immense and growing impact on medicine and society : vaccines against pandemics, monoclonal antibodies – the most successful class of drugs, breakthrough cures of cancer and autoimmune diseases, and new hopes to fight degenerative diseases. As immunologists and serial entrepreneurs, we contributed, at our small individual scale, to this biopharmaceutical revolution driven by immunology. We now join forces at Remora Biotech to leverage our entrepreneurial experience and, thanks to our supporting investors, to scale-up our ability to nurture and develop innovative life-changing immunotherapies. With our growing team and network of academic partners, business-oriented scientists, patent experts, drug developers and finance professionals, we create, finance, and manage a portfolio of daughter companies from discovery to clinical proof-of-concept. We aim at maximizing their odds of success and their strategic value for pharma partners while keeping capital efficient. Investors keen to gain exposure to this high-growth and high-impact sector, under the leadership of seasoned entrepreneurs, may become a shareholder of Remora Biotech and co-invest in our daughter companies.